The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set ...

22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...

The new 30-second commercial begins with a highlight clip of the Indiana Fever guard, known for shooting far behind the three-point line, shooting a three-pointer from the court logo.

and Independent Non-Executive Director at Roche Holding AG since 2022. Former jobs include Member of the Economic Action Council at Government of Malaysia from 2020 to 2021 and Trustee at Jeffrey ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Roche’s NGS technology is tailored to surpass traditional sequencing method limitations. Credit: Michael Vi/Shutterstock. Roche is set to partner with Broad Clinical Labs for developing pilot ...

Spanish investment management firm Cobas AM takes stake in Origin Enterprises 10:47 What the papers say: Trump’s tariff threat shakes pensions; Harris warns Lutnick on pharma; EU nears climate goals ...

The snow cap on the left side of the logo is shaped like the state of Utah. The jagged lines underneath it form an “M” for “Mammoth.” The tusk is shaped like a “U.” This was intentional — it stands ...

Visit a quote page and your recently viewed tickers will be displayed here.

Cobas Asset Management, the Spanish hedge fund which was previously the largest shareholder ...